{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:20:57Z","timestamp":1793859657300,"version":"4.6.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["UKDRI-3003"],"award-info":[{"award-number":["UKDRI-3003"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alzheimer\u2019s disease (AD) has been associated with immune dysregulation in biomarker and genome-wide association studies (GWAS). GWAS hits include the genes encoding complement regulators clusterin (<jats:italic>CLU<\/jats:italic>) and complement receptor 1 (<jats:italic>CR1<\/jats:italic>), recognised as key players in AD pathology, and complement proteins have been proposed as biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>To address whether changes in plasma complement protein levels in AD relate to AD-associated complement gene variants we first measured relevant plasma complement proteins (clusterin, C1q, C1s, CR1, factor H) in a large cohort comprising early onset AD (EOAD; n\u2009=\u2009912), late onset AD (LOAD; n\u2009=\u2009492) and control (n\u2009=\u2009504) donors. Clusterin and C1q were significantly increased (p\u2009&lt;\u20090.001) and sCR1 and factor H reduced (p\u2009&lt;\u20090.01) in AD plasma versus controls. ROC analyses were performed to assess utility of the measured complement biomarkers, alone or in combination with amyloid beta, in predicting AD. C1q was the most predictive single complement biomarker (AUC 0.655 LOAD, 0.601 EOAD); combining C1q with other complement or neurodegeneration makers through stepAIC-informed models improved predictive values slightly. Effects of GWS SNPs (rs6656401, rs6691117 in <jats:italic>CR1<\/jats:italic>; rs11136000, rs9331888 in <jats:italic>CLU<\/jats:italic>; rs3919533 in <jats:italic>C1S<\/jats:italic>) on protein concentrations were assessed by comparing protein levels in carriers of the minor vs major allele. To identify new associations between SNPs and changes in plasma protein levels, we performed a GWAS combining genotyping data in the cohort with complement protein levels as endophenotype. SNPs in <jats:italic>CR1<\/jats:italic> (rs6656401), <jats:italic>C1S<\/jats:italic> (rs3919533) and <jats:italic>CFH<\/jats:italic> (rs6664877) reached significance and influenced plasma levels of the corresponding protein, whereas SNPs in <jats:italic>CLU<\/jats:italic> did not influence clusterin levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Complement dysregulation is evident in AD and may contribute to pathology. AD-associated SNPs in <jats:italic>CR1<\/jats:italic>, <jats:italic>C1S<\/jats:italic> and <jats:italic>CFH<\/jats:italic> impact plasma levels of the encoded proteins, suggesting a mechanism for impact on disease risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-023-02850-6","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:02:01Z","timestamp":1689940921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Alzheimer\u2019s disease-associated complement gene variants influence plasma complement protein levels"],"prefix":"10.1186","volume":"20","author":[{"given":"Aurora","family":"Veteleanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Stevenson-Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Keat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Daskoulidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Escott-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioleta M.","family":"Zelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Carpanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan Paul","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"issue":"1","key":"2850_CR1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.trci.2019.06.001","volume":"5","author":"R Wittenberg","year":"2019","unstructured":"Wittenberg R, Knapp M, Karagiannidou M, Dickson J, Schott JM. Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer\u2019s disease patients. Alzheimers Dement (N Y). 2019;5(1):382\u20137.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"5580","key":"2850_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science"},{"issue":"2","key":"2850_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/JAD-180179","volume":"65","author":"O Zolochevska","year":"2018","unstructured":"Zolochevska O, Bjorklund N, Woltjer R, Wiktorowicz JE, Taglialatela G. Postsynaptic proteome of non-demented individuals with Alzheimer\u2019s disease neuropathology. J Alzheimers Dis. 2018;65(2):659\u201382.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"2850_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2850_CR5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","volume":"92","author":"D Alcolea","year":"2021","unstructured":"Alcolea D, Delaby C, Munoz L, Torres S, Estelles T, Zhu N, et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J Neurol Neurosurg Psychiatry. 2021;92(11):1206\u201314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2850_CR6","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Dage JL, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342.","journal-title":"Nat Med"},{"issue":"9","key":"2850_CR7","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.3390\/ijms23095202","volume":"23","author":"JA Flores-Cordero","year":"2022","unstructured":"Flores-Cordero JA, Perez-Perez A, Jimenez-Cortegana C, Alba G, Flores-Barragan A, Sanchez-Margalet V. Obesity as a risk factor for dementia and Alzheimer\u2019s disease: the role of leptin. Int J Mol Sci. 2022;23(9):5202.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2850_CR8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/biomedicines10040778","volume":"10","author":"A Athanasaki","year":"2022","unstructured":"Athanasaki A, Melanis K, Tsantzali I, Stefanou MI, Ntymenou S, Paraskevas SG, et al. Type 2 diabetes mellitus as a risk factor for Alzheimer\u2019s disease: review and meta-analysis. Biomedicines. 2022;10(4):778.","journal-title":"Biomedicines"},{"issue":"4","key":"2850_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00384-022-04131-9","volume":"37","author":"MN Zhang","year":"2022","unstructured":"Zhang MN, Shi YD, Jiang HY. The risk of dementia in patients with inflammatory bowel disease: a systematic review and meta-analysis. Int J Colorectal Dis. 2022;37(4):769\u201375.","journal-title":"Int J Colorectal Dis"},{"issue":"3","key":"2850_CR10","first-page":"170","volume":"5","author":"VK Khemka","year":"2014","unstructured":"Khemka VK, Ganguly A, Bagchi D, Ghosh A, Bir A, Biswas A, Chattopadhyay S, Chakrabarti S. Raised serum proinflammatory cytokines in Alzheimer\u2019s disease with depression. Aging Dis. 2014;5(3):170\u20136.","journal-title":"Aging Dis"},{"issue":"1\u20133","key":"2850_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0304-3940(89)90843-4","volume":"107","author":"PL McGeer","year":"1989","unstructured":"McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain-tissue of Alzheimer patients. Neurosci Lett. 1989;107(1\u20133):341\u20136.","journal-title":"Neurosci Lett"},{"issue":"2","key":"2850_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/01.wad.0000165506.60370.94","volume":"19","author":"H Zanjani","year":"2005","unstructured":"Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, et al. Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord. 2005;19(2):55\u201366.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"2850_CR13","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.4049\/jimmunol.152.10.5050","volume":"152","author":"HX Jiang","year":"1994","unstructured":"Jiang HX, Burdick D, Glabe CG, Cotman CW, Tenner AJ. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the c1q a-chain. J Immunol. 1994;152(10):5050\u20139.","journal-title":"J Immunol"},{"issue":"11","key":"2850_CR14","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/pro.4189","volume":"30","author":"NJ Geraghty","year":"2021","unstructured":"Geraghty NJ, Satapathy S, Kelly M, Cheng F, Lee A, Wilson MR. Expanding the family of extracellular chaperones: identification of human plasma proteins with chaperone activity. Protein Sci. 2021;30(11):2272\u201386.","journal-title":"Protein Sci"},{"key":"2850_CR15","doi-asserted-by":"publisher","first-page":"208.e1","DOI":"10.1016\/j.neurobiolaging.2015.09.009","volume":"37","author":"Y Deming","year":"2016","unstructured":"Deming Y, Xia J, Cai YF, Lord J, Holmans P, Bertelsen S, et al. A potential endophenotype for Alzheimer\u2019s disease: cerebrospinal fluid clusterin. Neurobiol Aging. 2016;37:208.e1-208.e9.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"2850_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2174\/15672050113106660162","volume":"10","author":"GM Mullan","year":"2013","unstructured":"Mullan GM, McEneny J, Fuchs M, McMaster C, Todd S, McGuinness B, et al. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer\u2019s disease. Curr Alzheimer Res. 2013;10(9):973\u20138.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"2850_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41593-020-0599-5","volume":"23","author":"R Sims","year":"2020","unstructured":"Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer\u2019s disease. Nat Neurosci. 2020;23(3):311\u201322.","journal-title":"Nat Neurosci"},{"issue":"4","key":"2850_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54(4):412\u201336.","journal-title":"Nat Genet"},{"issue":"10","key":"2850_CR19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet. 2009;41(10):1094\u20139.","journal-title":"Nat Genet"},{"issue":"5","key":"2850_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biopsych.2012.05.026","volume":"73","author":"M Thambisetty","year":"2013","unstructured":"Thambisetty M, Beason-Held LL, An Y, Kraut M, Nalls M, Hernandez DG, et al. Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry. 2013;73(5):399\u2013405.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2850_CR21","doi-asserted-by":"publisher","first-page":"1766.e5","DOI":"10.1016\/j.neurobiolaging.2015.01.006","volume":"36","author":"R Mahmoudi","year":"2015","unstructured":"Mahmoudi R, Kisserli A, Novella JL, Donvito B, Drame M, Reveil B, et al. Alzheimer\u2019s disease is associated with low density of the long CR1 isoform. Neurobiol Aging. 2015;36(4):1766.e5-1766.e12.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"2850_CR22","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/npp.2015.232","volume":"41","author":"DF Zhang","year":"2016","unstructured":"Zhang DF, Li J, Wu H, Cui Y, Bi R, Zhou HJ, et al. CFH variants affect structural and functional brain changes and genetic risk of Alzheimer\u2019s disease. Neuropsychopharmacol. 2016;41(4):1034\u201345.","journal-title":"Neuropsychopharmacol"},{"issue":"6","key":"2850_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ajmg.b.30668","volume":"147B","author":"M Zetterberg","year":"2008","unstructured":"Zetterberg M, Landgren S, Andersson ME, Palm\u00e9r MS, Gustafson DR, Skoog I, et al. Association of complement factor H Y402H gene polymorphism with Alzheimer\u2019s disease. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):720\u20136.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"1","key":"2850_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1212\/WNL.0b013e318204a397","volume":"76","author":"S Kim","year":"2011","unstructured":"Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, et al. Genome-wide association study of CSF biomarkers A beta(1\u201342), t-tau, and p-tau(181p) in the ADNI cohort. Neurology. 2011;76(1):69\u201379.","journal-title":"Neurology"},{"issue":"23","key":"2850_CR25","doi-asserted-by":"publisher","first-page":"8050","DOI":"10.1073\/pnas.0801227105","volume":"105","author":"JSK Kauwe","year":"2008","unstructured":"Kauwe JSK, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Nat Acad Sci USA. 2008;105(23):8050\u20134.","journal-title":"Proc Nat Acad Sci USA"},{"issue":"2","key":"2850_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11682-013-9262-z","volume":"8","author":"L Shen","year":"2014","unstructured":"Shen L, Thompson PM, Potkin SG, Bertram L, Farrer LA, Foroud TM, et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav. 2014;8(2):183\u2013207.","journal-title":"Brain Imaging Behav"},{"issue":"2","key":"2850_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuron.2013.02.026","volume":"78","author":"C Cruchaga","year":"2013","unstructured":"Cruchaga C, Kauwe JSK, Harari O, Jin SC, Cai YF, Karch CM, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer\u2019s disease. Neuron. 2013;78(2):256\u201368.","journal-title":"Neuron"},{"key":"2850_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2377-10-90","volume":"10","author":"MR Han","year":"2010","unstructured":"Han MR, Schellenberg GD, Wang LS. Alzheimer\u2019s Disease Neuroimaging Initiative. Genome-wide association reveals genetic effects on human A\u03b242 and \u03c4 protein levels in cerebrospinal fluids: a case control study. BMC Neurol. 2010;10:90.","journal-title":"BMC Neurol"},{"issue":"1","key":"2850_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/schbul\/sbn155","volume":"35","author":"SG Potkin","year":"2009","unstructured":"Potkin SG, Turner JA, Guffanti G, Lakatos A, Fallon JH, Nguyen DD, et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr Bull. 2009;35(1):96\u2013108.","journal-title":"Schizophr Bull"},{"issue":"1","key":"2850_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40142-014-0031-0","volume":"2","author":"C Cruchaga","year":"2014","unstructured":"Cruchaga C, Ebbert MW, Kauwe JK. Genetic discoveries in AD using CSF amyloid and tau. Curr Genet Med Rep. 2014;2(1):23\u20139.","journal-title":"Curr Genet Med Rep"},{"issue":"1","key":"2850_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1192\/bjp.174.1.45","volume":"174","author":"C Holmes","year":"1999","unstructured":"Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer\u2019s disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry. 1999;174(1):45\u201350.","journal-title":"Br J Psychiatry"},{"key":"2850_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1755-8794-1-44","volume":"1","author":"R Abraham","year":"2008","unstructured":"Abraham R, Moskvina V, Sims R, Hollingworth P, Morgan A, Georgieva L, et al. A genome-wide association study for late-onset Alzheimer\u2019s disease using DNA pooling. Bmc Med Genom. 2008;1:44.","journal-title":"Bmc Med Genom"},{"issue":"1","key":"2850_CR33","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1038\/s41467-021-24082-z","volume":"12","author":"G Leonenko","year":"2021","unstructured":"Leonenko G, Baker E, Stevenson-Hoare J, Sierksma A, Fiers M, Williams J, et al. Identifying individuals with high risk of Alzheimer\u2019s disease using polygenic risk scores. Nat Commun. 2021;12(1):4506.","journal-title":"Nat Commun"},{"key":"2850_CR34","first-page":"69","volume":"146","author":"J Stevenson-Hoare","year":"2022","unstructured":"Stevenson-Hoare J, Heslegrave A, Leonenko G, Fathalla D, Bellou E, Luckcuck L, et al. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer\u2019s disease. Brain. 2022;146:69.","journal-title":"Brain"},{"issue":"10","key":"2850_CR35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet. 2009;41(10):1088-U1061.","journal-title":"Nat Genet"},{"issue":"10","key":"2850_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/ng.3656","volume":"48","author":"S Das","year":"2016","unstructured":"Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48(10):1284\u20137.","journal-title":"Nat Genet"},{"key":"2850_CR37","doi-asserted-by":"crossref","unstructured":"The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526(7571):68\u201374.","DOI":"10.1038\/nature15393"},{"issue":"1","key":"2850_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang CC, Chow CC, Tellier L, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4(1):7.","journal-title":"Gigascience"},{"issue":"18","key":"2850_CR39","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1093\/bioinformatics\/btab186","volume":"37","author":"AP Boughton","year":"2021","unstructured":"Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, Boehnke M. LocusZoom.js: interactive and embeddable visualization of genetic association study results. Bioinformatics. 2021;37(18):3017\u20138.","journal-title":"Bioinformatics"},{"issue":"3","key":"2850_CR40","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S0002-9440(10)65340-0","volume":"154","author":"K Yasojima","year":"1999","unstructured":"Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer\u2019s disease brain. Am J Pathol. 1999;154(3):927\u201336.","journal-title":"Am J Pathol"},{"issue":"1","key":"2850_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/exnr.1999.7260","volume":"161","author":"SD Webster","year":"2000","unstructured":"Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Complement component C1q modulates the phagocytosis of A beta by microglia. Exp Neurol. 2000;161(1):127\u201338.","journal-title":"Exp Neurol"},{"key":"2850_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2019.110650","volume":"124","author":"N Hasegawa","year":"2019","unstructured":"Hasegawa N, Fujie S, Horii N, Uchida M, Toyama Y, Inoue K, et al. Aging-induced elevation in circulating complement C1q level is associated with arterial stiffness. Exp Gerontol. 2019;124: 110650.","journal-title":"Exp Gerontol"},{"issue":"13","key":"2850_CR43","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1074\/jbc.M115.689539","volume":"291","author":"M Beeg","year":"2016","unstructured":"Beeg M, Stravalaci M, Romeo M, Carra AD, Cagnotto A, Rossi A, et al. Clusterin binds to A(1\u201342) oligomers with high affinity and interferes with peptide aggregation by inhibiting primary and secondary nucleation. J Biol Chem. 2016;291(13):6958\u201366.","journal-title":"J Biol Chem"},{"issue":"5","key":"2850_CR44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","volume":"27","author":"RD Bell","year":"2007","unstructured":"Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer\u2019s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27(5):909\u201318.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"33","key":"2850_CR45","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.1073\/pnas.1701137114","volume":"114","author":"AM Wojtas","year":"2017","unstructured":"Wojtas AM, Kang SS, Olley BM, Gatherer M, Shinohara M, Lozano PA, et al. Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. Proc Nat Acad Sci USA. 2017;114(33):6962\u201371.","journal-title":"Proc Nat Acad Sci USA"},{"issue":"3","key":"2850_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3233\/JAD-2011-110251","volume":"25","author":"B Schurmann","year":"2011","unstructured":"Schurmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller SG, Pentzek M, et al. Association of the Alzheimer\u2019s disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis. 2011;25(3):421\u20134.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2850_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-017-0319-x","volume":"9","author":"JL Hsu","year":"2017","unstructured":"Hsu JL, Lee WJ, Liao YC, Wang SJ, Fuh JL. The clinical significance of plasma clusterin and A beta in the longitudinal follow-up of patients with Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):91.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2850_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nsmb.2191","volume":"19","author":"P Narayan","year":"2011","unstructured":"Narayan P, Orte A, Clarke RW, Bolognesi B, Hook S, Ganzinger KA, et al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-beta(1\u201340) peptide. Nat Struct Mol Biol. 2011;19(1):79\u201383.","journal-title":"Nat Struct Mol Biol"},{"issue":"10","key":"2850_CR49","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1096\/fj.06-7986com","volume":"21","author":"JJ Yerbury","year":"2007","unstructured":"Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, Wilson MR. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB. 2007;21(10):2312\u201322.","journal-title":"FASEB"},{"issue":"7","key":"2850_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0024-3205(96)00685-6","volume":"60","author":"M Shayo","year":"1997","unstructured":"Shayo M, McLay RN, Kastin AJ, Banks WA. The putative blood\u2013brain barrier transporter for the beta-amyloid binding protein apolipoprotein J is saturated at physiological concentrations. Life Sci. 1997;60(7):115-PL118.","journal-title":"Life Sci"},{"issue":"7","key":"2850_CR51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archgenpsychiatry.2010.78","volume":"67","author":"M Thambisetty","year":"2010","unstructured":"Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010;67(7):739\u201348.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"2850_CR52","doi-asserted-by":"publisher","first-page":"fcz003","DOI":"10.1093\/braincomms\/fcz003","volume":"1","author":"RJ Jackson","year":"2019","unstructured":"Jackson RJ, Rose J, Tulloch J, Henstridge C, Smith C, Spires-Jones TL. Clusterin accumulates in synapses in Alzheimer\u2019s disease and is increased in apolipoprotein E4 carriers. Brain Commun. 2019;1(1):fcz003.","journal-title":"Brain Commun."},{"issue":"6","key":"2850_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034078","volume":"7","author":"F Song","year":"2012","unstructured":"Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B, et al. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS ONE. 2012;7(6): e34078.","journal-title":"PLoS ONE"},{"issue":"1","key":"2850_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12017-015-8381-7","volume":"18","author":"A Montanola","year":"2016","unstructured":"Montanola A, de Retana SF, Lopez-Rueda A, Merino-Zamorano C, Penalba A, Fernandez-Alvarez P, et al. ApoA1, ApoJ and ApoE plasma levels and genotype frequencies in cerebral amyloid angiopathy. Neuromolecular Med. 2016;18(1):99\u2013108.","journal-title":"Neuromolecular Med"},{"issue":"6","key":"2850_CR55","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/glia.24355","volume":"71","author":"N Daskoulidou","year":"2023","unstructured":"Daskoulidou N, Shaw B, Torvell M, Watkins L, Cope EL, Carpanini SM, et al. Complement receptor 1 is expressed on brain cells and in the human brain. Glia. 2023;71(6):1522\u201335.","journal-title":"Glia"},{"issue":"6","key":"2850_CR56","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jalz.2019.03.007","volume":"15","author":"AR Morgan","year":"2019","unstructured":"Morgan AR, Touchard S, Leckey C, O\u2019Hagan C, Nevado-Holgado AJ, Barkhof F, et al. Inflammatory biomarkers in Alzheimer\u2019s disease plasma. Alzheimers Dement. 2019;15(6):776\u201387.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2850_CR57","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.3390\/ijms19082175","volume":"19","author":"R Mahmoudi","year":"2018","unstructured":"Mahmoudi R, Feldman S, Kisserli A, Duret V, Tabary T, Bertholon LA, et al. Inherited and acquired decrease in complement receptor 1 (CR1) density on red blood cells associated with high levels of soluble CR1 in Alzheimer\u2019s disease. Int J Mol Sci. 2018;19(8):2175.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2850_CR58","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ana.22277","volume":"69","author":"LB Chibnik","year":"2011","unstructured":"Chibnik LB, Shulman JM, Leurgans SE, Schneider JA, Wilson RS, Tran D, et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol. 2011;69(3):560\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"2850_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149792","volume":"11","author":"MI Fonseca","year":"2016","unstructured":"Fonseca MI, Chu SH, Pierce AL, Brubaker WD, Hauhart RE, Mastroeni D, et al. Analysis of the putative role of CR1 in Alzheimer\u2019s disease: genetic association, expression and function. PLoS ONE. 2016;11(2): e0149792.","journal-title":"PLoS ONE"},{"issue":"1","key":"2850_CR60","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s12035-015-9638-8","volume":"54","author":"XC Zhu","year":"2017","unstructured":"Zhu XC, Wang HF, Jiang T, Lu H, Tan MS, Tan CC, et al. Effect of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer\u2019s disease cohorts. Mol Neurobiol. 2017;54(1):551\u201362.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"2850_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150672","volume":"11","author":"PE Khoonsari","year":"2016","unstructured":"Khoonsari PE, Haggmark A, Lonnberg M, Mikus M, Kilander L, Lannfelt L, et al. Analysis of the cerebrospinal fluid proteome in Alzheimer\u2019s disease. PLoS ONE. 2016;11(3): e0150672.","journal-title":"PLoS ONE"},{"issue":"2","key":"2850_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1590\/0004-282x20190151","volume":"78","author":"G Lu","year":"2020","unstructured":"Lu G, Liu WH, Huang XY, Zhao YX. Complement factor H levels are decreased and correlated with serum C-reactive protein in late-onset Alzheimer\u2019s disease. Arq Neuro-Psiquiatr. 2020;78(2):76\u201380.","journal-title":"Arq Neuro-Psiquiatr"},{"issue":"2","key":"2850_CR63","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2019.07.018","volume":"16","author":"F Brosseron","year":"2020","unstructured":"Brosseron F, Kolbe CC, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, et al. Multicenter Alzheimer\u2019s and Parkinson\u2019s disease immune biomarker verification study. Alzheimers Dement. 2020;16(2):292\u2013304.","journal-title":"Alzheimers Dement"},{"issue":"19","key":"2850_CR64","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.3390\/ijms21197290","volume":"21","author":"A Ashok","year":"2020","unstructured":"Ashok A, Singh N, Chaudhary S, Bellamkonda V, Kritikos AE, Wise AS, et al. Retinal degeneration and Alzheimer\u2019s disease: an evolving link. Int J Mol Sci. 2020;21(19):7290.","journal-title":"Int J Mol Sci"},{"key":"2850_CR65","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.preteyeres.2017.09.001","volume":"62","author":"CB Toomey","year":"2018","unstructured":"Toomey CB, Johnson LV, Bowes RC. Complement factor H in AMD: bridging genetic associations and pathobiology. Prog Retin Eye Res. 2018;62:38\u201357.","journal-title":"Prog Retin Eye Res"},{"issue":"7708","key":"2850_CR66","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","volume":"558","author":"BB Sun","year":"2018","unstructured":"Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73\u20139.","journal-title":"Nature"},{"issue":"10","key":"2850_CR67","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.it.2012.06.001","volume":"33","author":"CL Harris","year":"2012","unstructured":"Harris CL, Heurich M, de Cordoba SR, Morgan BP. The complotype: dictating risk for inflammation and infection. Trends Immunol. 2012;33(10):513\u201321.","journal-title":"Trends Immunol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-023-02850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-023-02850-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-023-02850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:02:05Z","timestamp":1689984125000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-023-02850-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1186\/s12974-023-02850-6","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Multi-centre Research Ethics Committee, relevant local ethics committees and NHS trusts in the recruiting regions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). BPM serves as a consultant for Kira Pharmaceuticals and as an advisory board member for Complement Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}